文献速递免疫规划传染病防控与疫情报告

灭活流感疫苗的非特异性效应:一项检测阴性设计研究——灭活流感疫苗与SARS-CoV-2感染

Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
PubMed 文献 · Vaccine · 2024-04-23

本研究采用检测阴性设计,纳入2021年11月8日至2022年3月11日在荷兰社区检测点因COVID-19样症状检测的≥60岁成人,分析灭活流感疫苗(IIV)与SARS-CoV-2感染的关联。结果显示IIV与SARS-CoV-2感染无显著关联(完全调整OR 1.07,95%CI 0.78-1.49),时间交互项不显著(1.04,95%CI 0.51-2.15,p=0.91)。作者认为该研究未提示IIV对SARS-CoV-2感染有正负效应,需更大检测阴性设计或自控病例系列设计研究确认。

要点

  • 在≥60岁成人中,IIV与SARS-CoV-2感染无显著关联(完全调整OR 1.07,95%CI 0.78-1.49)。
  • IIV后不同日历时间段(2021年11月-2022年1月 vs 2022年2-3月)的交互项不显著(1.04,95%CI 0.51-2.15,p=0.91)。
  • 作者认为该检测阴性设计研究未提示IIV对SARS-CoV-2感染有正或负效应,需进一步研究确认。

核心结论

  • 尽管早期观察性研究提示IIV对SARS-CoV-2感染可能有保护性非特异性效应,但这项样本较小但控制良好的检测阴性设计研究未提示IIV对SARS-CoV-2感染有正或负效应。
  • 作者建议需更大规模的检测阴性设计研究或自控病例系列设计等替代设计来确认这些发现,并提供更明确的答案。

研究设计与样本

  • 检测阴性病例对照研究,在荷兰社区SARS-CoV-2检测点纳入2021年11月8日至2022年3月11日期间因COVID-19样症状检测的≥60岁成人。
  • 每次就诊常规收集2021年10-11月接种IIV的信息。
  • 采用逻辑回归计算未调整、部分调整(性别、年龄、教育水平)和完全调整(COVID-19疫苗接种、2020年IIV)的比值比(OR),比较SARS-CoV-2阳性与阴性者接种IIV的情况。
  • 通过纳入日历时间交互项(2021年11月-2022年1月 vs 2022年2-3月)探讨IIV后时间对SARS-CoV-2风险的差异效应。
  • 主分析共纳入1832名参与者,其中336人(18.3%)SARS-CoV-2检测阳性。

主要发现

  • IIV与SARS-CoV-2感染无显著关联,完全调整OR为1.07(95%CI 0.78-1.49)。
  • 时间段的交互项不显著(1.04,95%CI 0.51-2.15,p=0.91)。
  • 敏感性分析结果稳健。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous research suggested that the inactivated influenza vaccine (IIV) may protect against SARS-CoV-2 infection or a severe course of COVID-19. These findings were however based on cohort studies, that are prone to confounding by indication. We examined the association between IIV and SARS-Cov-2 infection in a Dutch population using a test-negative design. METHODS: This test-negative case-control study was conducted in adults (≥60) who tested because of COVID-19 like symptoms at community SARS-CoV-2 testing locations in the Netherlands during the period of November 8th 2021-March 11th 2022. Information on receipt of IIV in October-November 2021 was routinely collected at each visit. Logistic regression was used to calculate unadjusted, partially (sex, age, education level) and fully adjusted (COVID-19 vaccination, IIV 2020) odds ratios (ORs) for receipt of IIV in SARS-CoV-2 positive versus negative subjects. Differential effects on SARS-CoV-2 risk by time since IIV were investigated by including an interaction term for calendar time: November 2021-January 2022 vs February-March 2022. RESULTS: In total, 1,832 participants were included in the main analysis, of whom 336 (18.3 %) had a positive SARS-CoV-2 test. No significant association between IIV and SARS-CoV-2 infection was found; fully adjusted OR of 1.07 (95 % CI: 0.78-1.49). The interaction term for time periods was not significant (1.04 [95 % CI: 0.51-2.15], p = 0.91). Results were robust in sensitivity analyses. CONCLUSIONS: While earlier observational studies suggested a protective non-specific effect of IIV and SARS-CoV-2 infections, this smaller, but well controlled test-negative design study does not suggest an effect, either positive or negative. Larger test-negative design studies, or alternative designs such as the self-controlled case series design are needed to confirm these findings and provide more definite answers on the topic.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sellies AJ, Knol MJ, de Melker HE, et al. Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections. Vaccine. 2024. PMID: 38658205. doi:10.1016/j.vaccine.2024.04.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。